The Efficacy and Safety Associated with Switching from Concomitant Brimonidine and Ripasudil, or Brimonidine or Ripasudil Monotherapy to a Fixed Combination of Brimonidine and Ripasudil in Glaucoma Patients
Journal of Clinical Medicine · 16.07.2024 · 13 (14) · 4158
DOI: 10.3390/jcm13144158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.07.2024. Verfasst von Hiromitsu Onoe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, Hiroshima University, Hiroshima 734-8551, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
The purpose of this study was to investigate switching from brimonidine and ripasudil, and brimonidine or ripasudil, to a fixed combination of brimonidine and ripasudil, and evaluate the associated efficacy and safety in glaucoma patients.
Methods
Glaucoma patients undergoing treatment with at least brimonidine and ripasudil (n = 25) or treatment with at least brimonidine or ripasudil (n = 45) were evaluated in this retrospective study. After switching patients taking brimonidine and ripasudil, or brimonidine or ripasudil, to a ripasudil/brimonidine fixed-combination, ophthalmic suspension (RBFC), intra-ocular pressure (IOP), conjunctival hyperemia and superficial punctate keratopathy (SPK) were evaluated before and at 4, 12 and 24 weeks after switching to RBFC.
Results
No significant differences in the IOPs were observed after switching from brimonidine and ripasudil to RBFC. However, a significant decrease was observed at 4, 12 and 24 weeks in the baseline IOP, from 17.0 ± 4.4 mmHg to 15.7 ± 3.2 mmHg (p < 0.01), 14.3 ± 3.4 mmHg (p < 0.01) and 14.4 ± 4.1 mmHg (p < 0.01), respectively, after switching from brimonidine or ripasudil to RBFC. No significant changes were noted for the SPK score or conjunctival hyperemia score at any of the visits after switching to RBFC.
Conclusions
Throughout the 24-week evaluation period, the IOP was maintained after switching from brimonidine and ripasudil to RBFC. However, there was a significant decrease in the IOP after switching from brimonidine or ripasudil to RBFC. These results demonstrate that RBFC is safe for use in the treatment of glaucoma patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Science, Hiroshima University, Hiroshima 734-8551, Japan.
- Shirai Eye Hospital, Mitoyo 767-0001, Japan.
- Nagayama Eye Clinic, Okayama 714-0086, Japan.
- Hirota Eye Clinic, Yamaguchi 745-0017, Japan.
- Suzuki Eye Clinic, Yamaguchi 755-0155, Japan.
- Sagara Eye Clinic, Yamaguchi 758-0021, Japan.
ORCID-Profile: Hiromitsu Onoe, Katsuyoshi Suzuki, Yoshiaki Kiuchi
Zitieren
APA
Onoe, H., Hirooka, K., Baba, T., Nagayama, M., Hirota, A., Suzuki, K., Sagara, T., Mochizuki, H., & Kiuchi, Y. (2024). The Efficacy and Safety Associated with Switching from Concomitant Brimonidine and Ripasudil, or Brimonidine or Ripasudil Monotherapy to a Fixed Combination of Brimonidine and Ripasudil in Glaucoma Patients. Journal of Clinical Medicine, 13(14), 4158. https://doi.org/10.3390/jcm13144158
Vancouver
Onoe H, Hirooka K, Baba T, Nagayama M, Hirota A, Suzuki K, et al. The Efficacy and Safety Associated with Switching from Concomitant Brimonidine and Ripasudil, or Brimonidine or Ripasudil Monotherapy to a Fixed Combination of Brimonidine and Ripasudil in Glaucoma Patients. Journal of Clinical Medicine. 2024;13(14):4158. doi:10.3390/jcm13144158
BibTeX
@article{Onoe2024,
author = {Onoe, Hiromitsu and Hirooka, Kazuyuki and Baba, Tetsuya and Nagayama, Mikio and Hirota, Atsushi and Suzuki, Katsuyoshi and Sagara, Takeshi and Mochizuki, Hideki and Kiuchi, Yoshiaki},
title = {The Efficacy and Safety Associated with Switching from Concomitant Brimonidine and Ripasudil, or Brimonidine or Ripasudil Monotherapy to a Fixed Combination of Brimonidine and Ripasudil in Glaucoma Patients},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {14},
pages = {4158},
doi = {10.3390/jcm13144158}
}
EUVIMED